CFTR modulators and biologics have had a significant impact on the treatment of cystic fibrosis and severe asthma in recent years. Despite all the benefits that these active substances bring, some patients can also experience significant side effects. Some extrapulmonary consequences still receive too little attention in practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- From symptom to diagnosis
Oncology – Thymoma
- Shared decision making
Participatory decision-making using the example of diets for type 1 diabetes
- Patient-centered rounds in medicine
Aligning care with the patient
- Migraine and vascular regulation
CGRP-targeted migraine therapies for vascular risk patients
- Chronic and acute coronary syndrome
Proactive and evidence-based decision-making
- Pediatric multiple sclerosis
Early high efficacy as the key to improving prognosis
- Vaccinations against viral respiratory infections
Influenza, Covid-19 and RSV – Update 2025
- Case report, molecular basis and therapeutic implications